Asset
UMBRALISIB
TG THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (17)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02656303 | phase2 | terminated | 2016-01-07 | 2022-05-26 | TG Therapeutics, Inc. | A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304 |
| NCT02742090 | phase2 | terminated | 2016-04-21 | 2021-06-10 | TG Therapeutics, Inc. | Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy |
| NCT01767766 | phase1 | completed | 2013-01-07 | 2018-02-01 | TG Therapeutics, Inc. | Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies |
| NCT03207256 | phase2 | terminated | 2017-08-09 | 2022-05-25 | TG Therapeutics, Inc. | Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials |
| NCT02164006 | phase1 | completed | 2014-06-11 | 2016-05-01 | TG Therapeutics, Inc. | Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients |
FDA applications (0)
This company has no applications containing this asset.